Zoetis

Zoetis. It is a global leader in the discovery, development, manufacture, and commercialization of medicines, vaccines, and diagnostic products for companion animals and livestock. The company, which became an independent public entity via a spin-off from the pharmaceutical giant Pfizer in 2012, operates in more than 100 countries and maintains a significant research and development pipeline. Its portfolio is designed to support veterinarians, livestock producers, and pet owners in addressing health challenges across species including cattle, swine, poultry, fish, dogs, cats, and horses.

History

The origins of the company are deeply rooted within the animal health division of Pfizer, which had been built through decades of acquisitions and internal development. A key early foundation was Pfizer's purchase of the SmithKline Beecham animal health business in the 1990s. The decision to spin off the division was announced by Pfizer's then-CEO Ian Read as part of a strategy to streamline the parent company's focus on human pharmaceuticals. The initial public offering was completed in February 2013, marking the largest IPO in the United States since that of Facebook in 2012. Since its independence, the company has pursued a focused growth strategy, making significant acquisitions such as Abaxis, a point-of-care diagnostic firm, and Bayer's veterinary pharmaceuticals portfolio in certain markets, solidifying its position in the veterinary pharmaceutical industry.

Products and services

Its extensive portfolio is segmented across several therapeutic areas and species. Key product categories include vaccines, such as those for canine influenza and bovine respiratory disease; parasiticides like Simparica and Revolution for companion animals; anti-infectives; and medicated feed additives for livestock. The company also provides a range of diagnostic tools, including the VetScan analyzer platform acquired from Abaxis, and offers complementary services like technical support and veterinary training programs. Its products are marketed under well-known brands such as Apoquel for canine dermatology, Cytopoint, and Draxxin for cattle, serving both the companion animal and production animal markets globally.

Research and development

The company maintains a robust research and development enterprise, with major R&D facilities in locations like Kalamazoo, Michigan and Ghent, Belgium. Its innovation strategy focuses on advancing biologicals, monoclonal antibodies, and novel pharmaceutical compounds, often leveraging insights from human medical research conducted by organizations like the National Institutes of Health. Recent R&D successes include the development of Librela, a monoclonal antibody for canine osteoarthritis pain, and Solensia for cats, representing a new class of therapeutics. The pipeline is actively managed in collaboration with academic institutions, including the University of Pennsylvania School of Veterinary Medicine, and through partnerships with biotech firms to address emerging diseases and antimicrobial resistance.

Corporate affairs

Headquartered in Parsippany, New Jersey, the company is led by Chief Executive Officer Kristin Peck and operates with a regional structure encompassing the United States, Europe, Africa, the Middle East, and the Asia-Pacific region. It is a constituent of the S&P 500 and its shares trade on the New York Stock Exchange under the ticker symbol ZTS. The corporate strategy emphasizes sustainable operations, with commitments detailed in annual environmental, social, and governance reports, and active engagement in initiatives supported by the World Organisation for Animal Health to promote animal welfare and responsible antimicrobial use.

Animal health impact

The company's products and services have a substantial impact on global animal health and food security. Its vaccines and pharmaceuticals are critical for preventing and treating widespread diseases in livestock, such as those caused by Mannheimia haemolytica in cattle, thereby supporting the productivity and sustainability of farms worldwide. In companion animals, innovative therapies for chronic conditions like atopic dermatitis and arthritis have significantly improved quality of life for pets. Furthermore, its diagnostic tools enable faster clinical decisions in veterinary practices from Los Angeles to London, while its ongoing research into alternatives to antibiotics aligns with global public health goals advocated by the World Health Organization and the Food and Agriculture Organization of the United Nations.

Category:Animal health companies Category:Companies based in Morris County, New Jersey Category:Companies listed on the New York Stock Exchange